APUS

MATAWAN, N.J., Oct. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), today announced that NILA, the native token of the MindChain network, will be available on Pionex (https://www.pionex.com/en/), with trading scheduled to begin on Wednesday, Oct. 14, 2026, at 6 a.m. Eastern Time. The listing gives eligible users in the jurisdictions served by Pionex a direct, simple route to NILA on an established global exchange, ahead of NILA's planned move to its own network, MindChain. About Pionex Pionex is a global cryptocurrency exchange known for its built-in automated trading bots, incl

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

MATAWAN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), signed three agreements between Sept. 24 and Oct. 4, 2026, to build and operate dedicated blockchain networks for clients in climate finance, sports media and insurance, all running on MindChain. The three agreements follow the same model. MindWave builds and runs a dedicated network for each client on MindChain and is compensated through contracted fees or equity, together with an allocation equal to 20% of the credits or tokens issued on that client's network. Two of the three clients are U.S. companies, expandi

MATAWAN, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- via IBN – MindWave Innovations Inc. USA ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. ("BlockAssure") to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure's insurance and reinsurance operations on-chain. For MindWave, this is an important expansion of its U.S. business. It takes the company's technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client. "BlockAssure chose us to build AssureChain, and

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

MATAWAN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- MindWave Innovations Inc. ("MindWave"), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month software development and technology services agreement with New York-based Flash Sports & Media Holdings, Inc. (FLZH) to build and operate FlashChain, a blockchain for tracking digital broadcasting rights, video assets and match ticket inventory. Under the agreement, MindWave will deploy a dedicated subnet for FlashChain on MindChain's Layer-2 infrastructure, operate the validator nodes that run it, and issue FLZH the cryptographic keys and secure connections it needs to access the network. FLZH will own

MATAWAN, New Jersey, Sept. 24, 2026 (GLOBE NEWSWIRE) -- via IBN — MindWave Innovations Inc. ("MindWave"), a subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS), has signed a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. ("AQUAE") to deploy its MindChain infrastructure as the foundation of AQUAEChain, a platform for insured ALCI Credits. Under the agreement, MindWave will design, develop, deploy and host AQUAEChain, and provide technical support once it is live. The platform will manage the full life of an ALCI Credit: issuance, verification, tracking, transfer and retirement. MindWave will earn contracted software development and technology s

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals US, is developing institutional digital asset infrastructure connecting treasury, insurance, tokenized assets and blockchain ecosystems. Its platform combines insured custody, transparent reporting and technology-driven portfolio management to support risk-aware yield on Bitcoin reserves and institutional participation in the digital asset economy. As p

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

MATAWAN, New Jersey / GEORGE TOWN, Cayman Islands, Aug. 03, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc." or the "Company"), today announced that its NILA token is now available to eligible users in the United States on Webot, a licensed U.S. cryptocurrency exchange. Starting today, eligible U.S. users may access NILA on a licensed American platform for the first time. For anyone new to NILA, this makes it simpler to get started. Eligible users may access the token through a U.S. exchange that operates under applicable licenses, ahead of NILA moving to its own network, M

MATAWAN, New Jersey, and GEORGE TOWN, Cayman Islands, July 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- MindWave Innovations Inc., a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("MindWave Innovations Inc" or the "Company"), today announced MindChain, the world's first fully insured blockchain. MindChain is an insured, production-grade, EVM-compatible Layer 2 network that will go live in October 2026. It gives the MindWave ecosystem its own network, run by its own sequencer and validator set, while every transaction settles on Ethereum for final security. The Company also announced that the NILA token will be available to the U.S. market on Webot beginning Aug. 3,

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

NT 10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

Trading Expected to Resume on NYSE American on Tuesday, May 5 Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement of Lōkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS' common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 20

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

10-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)

8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)